

VolitionRx

15:00 20 Jul 2020

Small cap growth stocks in the spotlight at Proactive's virtual event on July 21

A select group of small cap stocks will join Proactive's Christine Corrado at the digital financial news organization's upcoming virtual investor conference on Tuesday, July 21 at 1pm EST.

The Virtual One2One event is an online variant of the popular conference format the media company has run for over a decade and enables communication between interested investors and some of North America's most innovative businesses.

Joining Proactive this time out are environmental engineering company BioLargo Inc (OTCQB: BLGO); VolitionRx Limited (NYSEAMERICAN:VNRX), a life sciences group, and digital media platform Bright Mountain Media (OTCQB:BMTM).

READ: BioLargo says subsidiary manufactures first AEC prototype to eliminate PFAS contaminants from water

Westminster, California-based BioLargo develops innovative products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds, and advanced wound care through a network of subsidiaries.

One subsidiary, BioLargo Engineering, Science & Technologies recently completed manufacturing on a first prototype unit of its patented BioLargo AEC (Aqueous Electrostatic Concentrator), that helps to effectively and affordably eliminate per-fluoroalkyl and poly-fluoroalkyl substances (PFAS) as contaminants from water.

"Our prototype is now ready for commercial trials, which is a big deal," BioLargo CEO Dennis Calvert told Proactive in a recent interview.

"The next step is to take that prototype and get it in the field with customers to prove out the metrics - basically, the economics and performance value - that will set the stage for a commercial launch."

The company is also working on a personal protection spray designed for face masks called Clyraguard.

READ: Volition reports promising clinical trials results for its novel coronavirus triage test

VolitionRx is an epigenetics company that develops easy-to-use blood-based cancer tests to accurately diagnose a range of cancers founded in 2010 by Cameron Reynolds, who is its current CEO.


The firm's NuQ platform looks for molecular signatures of cancer by focusing on the nucleosomes - a section of DNA wrapped around a core of proteins - in the blood.

However, the biotech group's work in developing a coronavirus (COVID-19) triage test is grabbing the headlines lately.

Price: 3.4

Market Cap: \$163.87 m

1 Year Share Price Graph



December 2019 June 2020 December 20

Share Information

Code: VNRX

Listing: NYSEMKT

52 week	High	Low
	5.36	2.22

Sector: Pharma & Biotech

Website: volitionrx.com

Company Synopsis:

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. .

action@proactiveinvestors.com

VolitionRx recently revealed promising results from two proof-of-concept clinical studies of the triage test using Nu.Q to predict the likelihood that a positive individual will develop complications and severe disease.

"Nu.Q has shown correlation with more severe COVID-19 cases implying strong prognostic potential, and we are now focused on the completion of larger longitudinal studies that would be needed to support a potential COVID-19 product launch," CEO Reynolds told investors in a recent statement.

"If we continue to see positive results in these longitudinal studies, we aim to have a CE-marked product available on multiple platforms in 2020 and will look to launch a low-cost product that could be used in any laboratory worldwide as soon as possible thereafter."

WATCH: Bright Mountain Media looks to uplist to the NYSE American Exchange

Bright Mountain Media is a holding company for valuable digital media properties and website titles around the world. The Boca Raton, FL-based firm owns Oceanside, a specialized video advertising services provider; MediaHouse, a data-driven technology to syndicate and monetize personalized video content; and Wild Sky Media, an interactive media company primarily geared towards a female audience with a 360 million-strong global reach.

COO Greg Peters joined Proactive earlier this month to talk about how the firm leverages its media properties to connect brands with targeted consumer demographics.

"Over the years, we've developed very specific, data-driven targeting," Peters told Proactive. "It starts with (understanding) the demographic going to our websites. We take that demographic, look at its value to certain brands, and target the ad agencies or companies that we know will value that audience."

Bright Mountain is hoping to uplist to the NYSE American exchange as it continues on the acquisition trail for new media titles.

To register for the July 21 event, please [click here](#).

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter [@AHarmantas](#)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).